Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C16H20ClN5O3 and a molecular weight of approximately 365.8 g/mol. It features a pyrazole core substituted with a piperazine ring and an N‑ethyl carboxamide group, as well as a chlorinated dihydroxyphenyl moiety. The structure suggests it is part of the phenylpyrazole class of compounds. There is no evidence that this molecule has been approved for any therapeutic use or entered clinical trials; its primary identification in chemical databases indicates it may be used in research settings as a tool compound or lead structure for further drug development[1][6][7]. No mechanism of action or biological target has been definitively established in public sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-piperazin-1-yl-1H-pyrazole-3-carboxamide.